0EVI Stock Overview A biotechnology company, develops immunotherapies for cancer patients in France and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Innate Pharma S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Innate Pharma Historical stock prices Current Share Price €1.94 52 Week High €2.79 52 Week Low €1.39 Beta 0.87 1 Month Change 25.97% 3 Month Change -4.17% 1 Year Change -21.61% 3 Year Change -57.75% 5 Year Change -67.06% Change since IPO -4.85%
Recent News & Updates
New minor risk - Share price stability Dec 09
Innate Pharma S.A., Annual General Meeting, May 22, 2025 Nov 21 Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025 Innate Pharma SA Announces Board Changes Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH). Sep 26
First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023) Sep 18 See more updates
New minor risk - Share price stability Dec 09
Innate Pharma S.A., Annual General Meeting, May 22, 2025 Nov 21 Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025 Innate Pharma SA Announces Board Changes Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH). Sep 26
First half 2024 earnings released: €0.31 loss per share (vs €0.021 profit in 1H 2023) Sep 18
No longer forecast to breakeven Jul 02 Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial Jun 18
New minor risk - Profitability Jun 05
No longer forecast to breakeven Jun 05
Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides Jun 05
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients Apr 16
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate Apr 10
Forecast to breakeven in 2026 Mar 26
Full year 2023 earnings released: €0.094 loss per share (vs €0.73 loss in FY 2022) Mar 22
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma Mar 06 Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million. Feb 07
Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 Dec 11
New minor risk - Share price stability Nov 13
Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023 Nov 03 Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024
Innate Pharma S.A. Provides Update on Lacutamab Clinical Program Oct 05
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023 Sep 22
First half 2023 earnings released: EPS: €0.021 (vs €0.08 in 1H 2022) Sep 17
Innate Pharma S.A. Announces Executive Changes Sep 15
Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma Jul 12
Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma Jul 11
Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer Jun 27
Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria Jun 17 Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress
Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies Jun 09 Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML May 27
No longer forecast to breakeven Mar 25
Innate Pharma SA Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology Jan 16
Innate Pharma S.A. Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022 Dec 11 Innate Pharma S.A. to Report First Half, 2023 Results on Sep 14, 2023
Innate Pharma SA Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides Sep 23
First half 2022 earnings released: EPS: €0.08 (vs €0.30 loss in 1H 2021) Sep 16
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study Aug 01
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer Jun 03
Innate Pharma S.A. Announces Supervisory Board Changes May 21
Innate Pharma Sa Announces the First Patient Was Dosed in A Phase 1/2 Clinical Trial Dec 16
Innate Pharma SA Announces That Data from the Phase 2 Expansion Cohort Dec 10
First half 2021 earnings released: €0.30 loss per share (vs €0.13 loss in 1H 2020) Sep 16
Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia Jul 07
Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides Jun 23
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting Jun 11
Innate Pharma S.A. Announces New Lacutamab Data from Tellomak Trial in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma Jun 10
Member of Supervisory Board Marcus Schindler has left the company Jun 05
Full year 2020 earnings released: €0.81 loss per share (vs €0.31 loss in FY 2019) Apr 30
Full year 2020 earnings released Mar 19
Innate Pharma S.A. Advances Lacutamab Clinical Development Program Feb 09
Innate's First NK Cell Engager Selected by Sanofi as Drug Candidate for Development Jan 05
Rosen Law Firm Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action Dec 17 Innate Pharma S.A., Annual General Meeting, May 28, 2021
Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome Nov 14 Innate Pharma S.A. Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome
Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients Nov 06
New 90-day low: €3.10 Sep 25
New 90-day low - €3.70 Sep 09
First half earnings released Sep 09 Shareholder Returns 0EVI GB Biotechs GB Market 7D -11.2% -5.1% -2.2% 1Y -21.6% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0EVI exceeded the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0EVI underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0EVI's price volatile compared to industry and market? 0EVI volatility 0EVI Average Weekly Movement 15.8% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0EVI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0EVI's weekly volatility has increased from 9% to 16% over the past year.
About the Company Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Show more Innate Pharma S.A. Fundamentals Summary How do Innate Pharma's earnings and revenue compare to its market cap? 0EVI fundamental statistics Market cap €155.75m Earnings (TTM ) -€34.05m Revenue (TTM ) €33.79m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0EVI income statement (TTM ) Revenue €33.79m Cost of Revenue €53.65m Gross Profit -€19.86m Other Expenses €14.20m Earnings -€34.05m
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 27, 2025
Earnings per share (EPS) -0.42 Gross Margin -58.77% Net Profit Margin -100.78% Debt/Equity Ratio 121.3%
How did 0EVI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 13:24 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Innate Pharma S.A. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Olga Smolentseva Bryan Garnier & Co Yigal Nochomovitz Citigroup Inc Michael Thomas Cooper Edison Investment Research
Show 12 more analysts 
